5-(2-Chloroethyl)-6-fluoro-2,3-dihydro-1H-indol-2-one | 118289-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(2-Chloroethyl)-6-fluoro-2,3-dihydro-1H-indol-2-one
• 英文别名: 5-(2-chloroethyl)-6-fluorooxindole；5-(2-Chloroethyl)-6-fluoro-1,3-dihydroindol-2-one
• CAS: 118289-53-5
• 化学式: C₁₀H₉ClFNO
• 分子量: 213.639
• InChiKey: LYLJGWHKMPQQDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2-Chloroethyl)-6-fluoro-2,3-dihydro-1H-indol-2-one 生成 5-(2-chloroethyl)-7-fluorooxindole
  参考文献：
  名称：

  Method of treating psychiatric conditions

  摘要：

  一种用于治疗精神疾病或障碍的方法，所述精神疾病或障碍包括恐慌症、创伤后应激障碍和恐惧症等焦虑障碍，焦虑的精神病性发作，与精神病相关的焦虑，严重的重性抑郁障碍等精神情绪障碍，以及急性躁狂或与双相情感障碍相关的抑郁等精神障碍，如双相情感障碍、精神发育迟滞的行为表现、行为障碍或自闭症障碍、阿尔茨海默病型痴呆症和药物诱导的运动障碍以及基于神经退行性的运动障碍等运动障碍，包括人类在内的哺乳动物，包括向所述哺乳动物投予上述化合物的药效有效量或其药学上可接受的酸盐加合物，其中n、X、Y和Ar如上所定义。

  公开号：

  US06245766B1
• 作为产物：
  描述：

  6-fluoro-5-(chloroacetyl)oxindole 在 三乙基硅烷 、 三氟乙酸 作用下， 生成 5-(2-Chloroethyl)-6-fluoro-2,3-dihydro-1H-indol-2-one
  参考文献：
  名称：

  3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents

  摘要：

  A series of substituted phenethyl derivatives of 3-benzisothiazolylpiperazine incorporating potent D-2 and 5-HT2A antagonist activity was investigated as an approach to a novel atypical antipsychotic agent. The in vitro profile of 8e from this series is a combination of D-2 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D-2 ratio comparable to the atypical agent clozapine. In vivo 8e possesses activity consistent with an efficacious antipsychotic agent with less tendency to induce extrapyramidal side effects in man.

  DOI：

  10.1021/jm950625l

文献信息

• Method of treating tourette's syndrome and obsessive compulsive disorder
  申请人：Pfizer Inc.

  公开号：US06127373A1

  公开（公告）日：2000-10-03

  A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  在哺乳动物，包括人类中，治疗抽动症、强迫症、慢性运动或发声抽动障碍的方法，包括向该哺乳动物施用公式##STR1##中的化合物或其药用可接受的酸盐的有效量，其中n、X、Y和Ar如上所定义。
• METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY
  申请人：——

  公开号：US20020004504A1

  公开（公告）日：2002-01-10

  A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula 1 or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.

  在哺乳动物中治疗青光眼和缺血性视网膜病的方法，包括向所述哺乳动物施用公式1的化合物或其药学上可接受的酸盐的治疗有效量，其中n、X、Y和Ar如规范中定义。
• Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice
  作者：P Srinivas、A.R Subramanian、P Brust、S.A.V Raghavan、J.B Rangisetty、C.N.V.H.B Gupta、N Sridhar、A Veeranjaneyulu、P Parimoo

  DOI：10.1016/s0014-827x(99)00058-0

  日期：1999.8

  antipsychotic agents, one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system. The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine (7) is described. Compound 7e, 5-2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2

  在开发新的非典型抗精神病药的研究中，一种策略是可以通过操纵血清素能系统来调节多巴胺能系统。描述了基于1-（1,2-二氢-2-ac烯基）哌嗪（7）结构的一系列潜在的非典型抗精神病药的合成和初步药理学评估。来自该系列的化合物7e，5- 2- [4-（1,2-二氢-2-ac烯基）哌嗪基]乙基} -2,3-二氢dro-1H-吲哚-2-酮在5-HT1A和5-HT2A受体对D2受体的亲和力适中。7e表现出由氟哌啶醇引起的僵直症的高度逆转，表明其非典型的抗精神病药性。
• Anxiety treatments with ziprasidone
  申请人：Romano Joseph Steven

  公开号：US20050004138A1

  公开（公告）日：2005-01-06

  The present invention, in one aspect, relates to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, situational anxiety, for example, anxiety experienced prior to medical procedures (e.g., surgery), public speaking, anxiety associated with swimming or water, anxiety associated with travel (e.g., air travel), or anxiety associated with specific phobias (snakes, spider, rats, sight of blood), comprising administering a pharmaceutically effective amount of a compound of formula I to the mammal. In another aspect, the present invention is directed to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, treatment-resistant anxiety, which method comprises administering a pharmaceutically effective amount of a compound of formula I to the mammal. The compounds of formula I are defined as follows: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明在某些方面涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的情境焦虑，例如在医疗程序（例如手术）、公共演讲、与游泳或水有关的焦虑、与旅行（例如空中旅行）有关的焦虑或与特定恐惧症（蛇、蜘蛛、老鼠、血液视觉）有关的焦虑，包括向哺乳动物投与化学有效量的式子I的化合物。在另一个方面，本发明涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的难治性焦虑，其中该方法包括向哺乳动物投与化学有效量的式子I的化合物。式子I的化合物定义如下：或其药学上可接受的酸盐，其中Ar、n、X和Y如上定义。
• Treatment of bipolar disorders and associated symptoms
  申请人：Romano Joseph Steven

  公开号：US20050038036A1

  公开（公告）日：2005-02-17

  The present invention relates to a method for treatments relating to bipolar disorder in a mammal, including a human, the treatments including treatment of rapid-cycling bipolar disorder, treatment of symptoms of bipolar disorder selected from the group consisting of acute mania and depression, treatment for effecting mood stabilization; treatment for preventing relapse into bipolar episodes, and for the treatment of suicidal thoughts and tendencies associated with bipolar disorder, comprising administering to said mammal an effective amount of a compound of the formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明涉及一种治疗哺乳动物（包括人类）的双相障碍的方法，包括治疗快速循环型双相障碍，治疗选自急性躁狂和抑郁症状的双相障碍症状，治疗以影响情绪稳定为目的的治疗，预防双相障碍复发的治疗，以及治疗与双相障碍相关的自杀思想和倾向。该方法包括向该哺乳动物施用以下化合物的有效量：式I的化合物或其药学上可接受的酸盐加合物，其中Ar、n、X和Y如定义。